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Table 1 Comparative results of three glanders serological tests on 182
equine sera from Bahrain expressed as positive percentage.
ID SAMPLE
NUMBER
CCPRO
CFT %
CVRL
cELISA%
FLI WB%
Horse Panel A 53 96.2 (51/53) 98.1 (52/53) 98.1 (52/53)
Horse Panel B 43 90.7 (39/43) 95.3 (41/43) 90.7 (39/43)
Horse Panel C 86 34.9 (30/86) 0 (0/86) 0 (0/86)
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Equine infectious anemia (EIA) is a disease of high economic
impact on the equine industry worldwide. Since horses are
frequent travelers, EIA falls under strict regulatory control pro-
grams in many countries. In Argentina the national animal health
authority (SENASA) states that all horses imported, moving
within the country, or congregating at public assemblies must
have a negative EIA report conducted within the previous 2
months. The agent causing EIA is a RNAvirus from the Retroviridae
family and its major capsid protein named p26 is the most
immunogenic protein in the viral particle. Thus, the detection of
speciﬁc antibodies directed to p26 is the aim ofmost diagnosis tests
available in the world. The agar gel immunodifusion (AGID) is the
ofﬁcially accepted method to certify the diagnosis of EIA in
Argentina. Since 2009 IncuINTAwas working on the scaling up and
production of the KIT AIE IDGA RP26, an Argentinean AGID test
entirely developed in the laboratory containing a recombinant p26
protein to detect EIA antibodies in horses’ serum. Until 2015
IncuINTA produced two pilot batches and six commercial batches
(one per year) containing from 24000 determinations in 2011 to
39600 determinations in 2015. Since the product was launched in
2011, the sales were increased 109%. Up to date we have placed on
the market 170640 determinations. As expected, the number of
laboratories buying the KIT AIE IDGA RP26 was also increasing
through time being 26 in 2011 and 36 in 2015. This number of
clients represents 17% of the 207 laboratories authorized by SENASA
to diagnose EIA in Argentina. These laboratories are located mostly
in Buenos Aires, Santa Fe, Entre Ríos, Formosa, La Pampa, Rio Negro,
Cordoba, Corrientes, Salta and Tucuman provinces. Until 2009 there
was no Argentinean EIA test available in our market being the
imported ones very expensive. IncuINTA,which is a R&D laboratory,
could scale up, produce and sell the KIT AIE IDGA RP26 during six
consecutive years. After this success, IncuINTA perspective is to
increase the number of batches each year to be able to attend the
demand of most diagnosis laboratories in the country.
Reference
Alvarez, I. et al. Standardization and validation of an agar
gel immunodiffusion test for the diagnosis of equine
infectious anemia using a recombinant p26 antigen. Vet.
Microbiol. 121, 344e351 (2007).
167
Detection of equine herpes virus in Uruguay
E.R. Castro*1, J. Murgia 2, A. Caramelli 2, J. Arbiza 3
1Department Virology Veterinary Laboratories Division (DILAVE)
MGAP, Montevideo, Uruguay; 2Division Animal Industry, MGAP,
Montevideo-Uruguay; 3 Section Virology Faculty of Science,
UDELAR, Montevideo, Uruguay
In recent years, an increase in the number of cases of equine
neurological disease caused by equine herpes virus 1 (EHV1)
neuropathogenic variants, has been observed in numerous
countries. The purpose of this study was to detect the presence of
the viral genome of EHV1 and equine herpes virus 4 (EHV4) in
bronchopulmonary lymph nodes of 47 horses, from various lo-
cations of Uruguay, obtained in a slaughterhouse. The genes
encoding the glycoprotein H (gH) of EHV1 and B (gB) of EHV4were ampliﬁed by a semi-nested PCR. Of the total samples
analyzed, 27% and 6% of lymph nodes contained the gene for gH
and gB, respectively. To determine whether the genomes of EHV1
possess the mutation associated with neuropathogenesis (G2254
/ D752), the gene for the viral DNA polymerase was ampliﬁed and
sequenced. One of the ﬁve genomes sequenced presented the
mutation. The results conﬁrm the presence of EHV1 in our
country. Furthermore, there is evidence for the ﬁrst-time detec-
tion of EHV4 and the neuropathogenic variant (G2254 / D752) of
EHV1 in Uruguay. This ﬁnding provides new insights into the
epidemiological situation of EHV-1 and EHV-4 in our country.
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Glanders is a zoonotic disease caused by Burkholderia mallei. It is
an OIE (Ofﬁce International des Epizooties) listed disease which
may affect a variety of animal species but mainly equids. For in-
ternational trade of horses, donkeys and mules, the complement
ﬁxation test (CFT) is the OIE acknowledgedmain test (OIEManual,
2016, in press). However, in recent years researches from different
countries have established new serological tests to overcome
cross reactions (Neubauer et al., 2005; Naureen et al., 2007;
Sprague et al., 2009 & Elschner et al., 2011) which sometimes
hamper international trade. Additionally, serological results from
donkeys andmules as well as from older equine samples are often
difﬁcult to interpret due to anti complementary reactions (Wer-
nery et al., 2012). An outbreak of glanders in Bahrain in 2010/11
(Scholz et al., 2014) provided the opportunity to compare
different serological tests on 182 equine sera. The 182 horses
tested included 53 horses with clinical glanders signs (Panel A),
43 horses which had direct contact with glanderous horses with
no glanders clinical signs (Panel B) and 86 horses with no clinical
signs kept in the outbreak area (Panel C). The results of the
comparison tests are presented in Table 1.References
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